PR Newswire#pr
Inhibrx Reports Second Quarter 2026 Financial Resultstranslating…
4h agoFactuality: 70/100USACision
SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the second quarter of 2026. The biopharmaceutical company has two programs in ongoing clinical trials. Recent Corporate Highlights…